40 results about "Proliferative vitreoretinopathy" patented technology

RNA interference is provided for inhibition of connective tissue growth factor mRNA expression in ocular disorders involving CTGF expression. Ocular disorders involving aberrant CTGF expression include glaucoma, macular degeneration, diabetic retinopathy, choroidal neovascularization, proliferative vitreoretinopathy and wound healing. Such disorders are treated by administering interfering RNAs of the present invention.

Antagonists of S1P3 (Edg-3) receptors are provided for attenuation of Smad signaling in a method of down-regulation of receptor signaling and downstream decreased production of connective tissue growth factor in ocular disorders involving CTGF accumulation. Ocular disorders involving inappropriate CTGF accumulation include ocular hypertension, glaucoma, glaucomatous retinopathy, optic neuropathy, macular degeneration, diabetic retinopathy, choroidal neovascularization, proliferative vitreoretinopathy and ocular wound healing, for example. Such disorders are treated by administering antagonists of the present invention.

A method of treating ocular disorders (such as, for example, proliferative vitreoretinopathy or PVR) associated with replicating ocular cells by transfecting replicating ocular cells in vivo with a polynucleotide encoding an agent which is capable of providing for the inhibition, prevention, or destruction of the growth of the replicating ocular cells upon expression of the agent. The agent may be a viral thymidine kinase, and the polynucleotide encoding the agent may be contained in a retroviral vector. Once the replicating ocular cells are transduced with the retroviral vector, the patient is given a chemotherapeutic or interaction agent, such as ganciclovir, which kills the transfected replicating ocular cells.

The present invention relates to method for the treatment or prevention and of proliferative eye diseases including but not limited to: age related macular degeneration associated proliferative retinopathy, proliferative diabetic retinopathy, proliferative vitreoretinopathy, posterior capsular opacification, scaring and fibrosis after glaucoma filtration surgery, uveal melanoma, and retinoblastoma. The method comprises contacting cells in the eye by means of intra-ocular injection or infusion, with a drug that irreversibly inhibits cellular proliferation without causing extensive tissue necrosis or cytotoxicity. In a preferred embodiment the drug is bizelesin.

The invention relates to a method for curing a plurality of ophthalmonogy diseases by degrading, blocking, combining and inhabiting vitreous bodies and/or pathogenic restricted substances in the retinal and using an insoluble biological activity protein as a intravitreal medicament according to the unique structure feature of the vitreous body cavity in eyeballs and the pathogenic functions of a plurality of vitreous bodies and/or the pathogenic restricted substances in the retinal of ophthalmonogy patients in a plurality of the ophthalmonogy diseases. For example, diabetic retinopathy, senile macular degeneration, ophthalmonogy diseases caused by retinal artery or vein occlusion, macular edema, proliferative vitreoretinopathy, intravitreal living cells, vitreous macular traction, macular pucker, macular exudate, fibrin deposition, retinopathy of prematurity, floaters, retinal tearing, retinal detachment, macula hole, epiretinal membrane, retinal internal limiting membrane causing surface tension, collagen fibers causing the traction function to the retinal and the like.

Antagonists of cation-independent mannose 6-phosphate/insulin-like growth factor-II receptor are provided for attenuation of CTGF signaling in a method of down-regulation of receptor signaling and downstream decreased signaling of connective tissue growth factor in ocular disorders involving inappropriate CTGF signaling. Ocular disorders involving inappropriate CTGF signaling include ocular hypertension, glaucoma, glaucomatous retinopathy, optic neuropathy, macular degeneration, diabetic retinopathy, choroidal neovascularization, and proliferative vitreoretinopathy, for example. Such disorders are treated by administering antagonists of the present invention.

The present invention discloses applications of Chalcomoracin and homologues thereof in preparation of drugs for treatment and prevention of proliferative vitreoretinopathy. The Chalcomoracin and homologues thereof can inhibit vitreous-induced AKT activation and p53 decline, block proliferation, migration and contraction of ARPE-19 cells stimulated by vitreous, and have effects of treating and preventing the proliferative vitreoretinopathy.

Glutamate causes migration and proliferation of retinal pigment epithelium and/or glial cells, and glutamate antagonists can prevent, treat or reduce retinal pigment epithelium and/or glial migration and the subsequent development of proliferative vitreoretinopathy. Avoidance or management of proliferative vitreoretinopathy can be achieved by administering to the patient a compound capable of reducing glutamate-induced retinal cell migration in a concentration effective to reduce such migration.

Disclosed herein are methods for treatment for proliferative vitreoretinopathy (PVR) by inhibiting the activity of activated transforming growth factor Beta activated kinase 1 (TAK-1), or activation thereof. Pharmaceutical compositions for use in the described treatments are also provided.

The invention discloses an application of circRNA in preparing a diagnostic reagent for proliferative vitreoretinopathy (PVR). The invention also discloses a circular RNA detection kit for PVR diagnosis. The kit mainly comprises an RNA extraction system, a reverse transcription reaction system, and a PCR reaction system. The relative contents of circRNA in vitreous and serum are detected by real-time fluorescence quantitative PCR technique for early diagnosis of PVR. The application of circRNA in preparing the diagnostic reagent for PVR has the advantages of small wound, high sensitivity and simple operation.

The present invention provides one kind of slow released 5-fluorouracil system in vitreous chamber. The slow released 5-fluorouracil system has medicine carrying amount of 10.44%, medicine carrier of synthesized biodegradable polymer polylactic acid, and emulsifier of water soluble polymer PVA. The slow released 5-fluorouracil system is suitable for use after the surgical operation on vitreoretinopathy, and after being injected into vitreous chamber, it may maintain smooth medicine release for 28 days to inhibit the proliferation of active cell inducing proliferative vitreoretinopathy, block the acting path of the cell factors and prevent proliferative vitreoretinopathy effectively.

The invention relates to a traditional Chinese medicine for treating proliferative vitreoretinopathy, which is prepared from leech, trigone, hawthorn, kelp, seaweed and other traditional Chinese medicines as raw materials.

The invention belongs to the technical field of traditional Chinese medicine, in particular to traditional Chinese medicine for treating proliferative diabetic retinopathy. The traditional Chinese medicine comprises, by weight, 5-13 parts of American ginseng, 8-16 parts of radix pseudostellariae, 8-16 parts of atractylodes macrocephala koidz, 11-15 parts of Chinese yam, 8-16 parts of prepared rehmannia roots, 8-16 parts of fruits of Chinese wolfberry, 8-16 parts of glossy privet fruits, 8-16 parts of seeds of Chinese dodder, 5-13 parts of ligusticum wallichii, 5-13 parts of corydalis tuber, 8-16 parts of salviae miltiorrhizae, 5-13 parts of Rhizoma Sparganii, 1-3 parts of leeches, 5-13 parts of rhizoma arisaematis, 2-4 parts of rhizoma typhonii, 8-16 parts of semen cassiae and 8-16 parts of seeds of feather cockscomb. The traditional Chinese medicine can effectively reduce the intraocular pressure and the thickness of yellow spots of an affected eye, reduce the leakage area of retinal neovascularization, promote retinal neovascularization to gradually vanish, improve the vision of a patient and improve the life quality of the patient.

The invention provides compositions and methods for treatment of proliferative vitreoretinopathy.

The invention discloses a derivative containing nitrogen heterocyclic rings and application of the derivative in retinal neovascularization diseases. The derivative has the biological structural formula shown in the description, wherein R1, R2, R3 and R4 are respectively and independently selected from -H or -CN. Under the same concentration of 5microg/mL, the growth inhibition ratios of the embodiment II, the embodiment III and the embodiment IV to HRCEC are superior to a monoclonal antibody drug Avastin. By injecting the compound into a vitreous body, the formation of pathologic new vesselscan be reduced, so that the derivative of the formula I or the salt of the derivative can be used for deeply researching and developing retinal neovascularization relevant diseases such as retinal vein occlusion, proliferative diabetic retinopathy, subretinal neovascular membrane, neovascular glaucoma, retinopathy of prematurity and proliferative vitreoretinopathy.

The present disclosure provides formulations of methotrexate for ocular administration, including intravitreal administration, and the use of the formulations for the treatment of proliferative vitreoretinopathy (PVR), intraocular lymphoma (e.g., PVRL), and intraocular inflammation.